The relationship between lung cancer histology and the clinicopathological characteristics of bone metastases

被引:39
|
作者
dos Reis Oliveira, Marcelo Braganca [1 ]
de Queiroz Mello, Fernanda Carvalho [2 ,3 ]
Machado Paschoal, Marcos Eduardo [3 ]
机构
[1] Univ Fed Rio de Janeiro, Trauma Orthopaed Serv, Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Fac Med, Rio De Janeiro, Brazil
[3] Univ Fed Rio de Janeiro, Thorac Dis Inst, Rio De Janeiro, Brazil
关键词
Lung cancer; Bone metastasis; SRE; Histology; SKELETAL-RELATED EVENTS; ZOLEDRONIC ACID; PROGNOSTIC-FACTORS; SOLID TUMORS; DOUBLE-BLIND; PHASE-III; SURVIVAL; EPIDEMIOLOGY; PREDICTORS; PLACEBO;
D O I
10.1016/j.lungcan.2016.03.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Lung cancer is the leading cause of death due to cancer, and bone is one of the most frequent sites of metastasis. However, there is no published evidence regarding an association between lung cancer histology and skeletal complications. Therefore, we evaluated the influence of lung cancer histology on the frequency of bone metastases (BMs), skeletal-related events (SREs), and survival after BM. Material and methods: This retrospective study evaluated medical records from 413 patients who were diagnosed with lung cancer between 2003 and 2012. The prevalences of BMs and SREs were calculated, and their associations with the histological subtypes were evaluated using the chi-square test, odds ratios (OR), and 95% confidence intervals (CI). Overall survivals and associations with the histological subtypes were evaluated using the Kaplan-Meier method and the log-rank test. Results: The prevalences of BM, synchronous BM, and SREs were 28.2%, 70.4%, and 68.7%, respectively. Adenocarcinoma was the most common histological subtype (46.7%), and was significantly more frequent among patients with BM (58.3% vs. 42.1%; p = 0.003; OR: 1.92; 95% CI: 1.29-2.97). Squamous cell was significantly less frequent among patients with BM (13.0% vs. 29.8%; p = 0.0004; OR: 0.35; 95% CI: 0.19-0.64). The median survival time after the first BM diagnosis was 4 months, and there was no significant difference in the survival periods for the various histological subtypes. Conclusion: Adenocarcinoma and squamous cell were significantly associated with higher and lower risks of developing BM, respectively. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 50 条
  • [21] Bone matters in lung cancer
    Brodowicz, T.
    O'Byrne, K.
    Manegold, C.
    ANNALS OF ONCOLOGY, 2012, 23 (09) : 2215 - 2222
  • [22] Long-term safety and efficacy of bisphosphonate therapy in advanced lung cancer with bone metastasis
    Wei, Zixin
    Pan, Bo
    Jia, Dexin
    Yu, Yan
    FUTURE ONCOLOGY, 2022, 18 (18) : 2257 - 2267
  • [23] Disease Progression Increases the Risk of Skeletal-Related Events in Patients With Bone Metastases From Castration-Resistant Prostate Cancer, Lung Cancer, or Other Solid Tumors
    Tchekmedyian, N. Simon
    Chen, Yin-Miao
    Saad, Fred
    CANCER INVESTIGATION, 2010, 28 (08) : 849 - 855
  • [24] Bone metastases in thyroid cancer
    Iniguez-Ariza, Nicole M.
    Bible, Keith C.
    Clarke, Bart L.
    JOURNAL OF BONE ONCOLOGY, 2020, 21
  • [25] Relationship between Contrast-Enhanced CT and Clinicopathological Characteristics and Prognosis of Non-Small Cell Lung Cancer
    Yang, Hai
    Fan, Heng-Xin
    Song, Li-Hong
    Xie, Ji-Cheng
    Fan, Shu-Feng
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (09) : 516 - 522
  • [26] Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid Subgroup Analysis from a Randomized Phase 3 Study
    Scagliotti, Giorgio Vittorio
    Hirsh, Vera
    Siena, Salvatore
    Henry, David H.
    Woll, Penella J.
    Manegold, Christian
    Solal-Celigny, Philippe
    Rodriguez, Gladys
    Krzakowski, Maciej
    Mehta, Nilesh D.
    Lipton, Lara
    Angel Garcia-Saenz, Jose
    Pereira, Jose Rodrigues
    Prabhash, Kumar
    Ciuleanu, Tudor-Eliade
    Kanarev, Vladimir
    Wang, Huei
    Balakumaran, Arun
    Jacobs, Ira
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (12) : 1823 - 1829
  • [27] Clinical outcome for small cell lung cancer patients with bone metastases at the time of diagnosis
    Gong, Linlin
    Xu, Liming
    Yuan, Zhiyong
    Wang, Zhongqiu
    Zhao, Lujun
    Wang, Ping
    JOURNAL OF BONE ONCOLOGY, 2019, 19
  • [28] Prospective analysis of the association between skeletal-related events and quality of life in patients with advanced lung cancer (CSP-HOR13)
    Kunikane, Hiroshi
    Yokota, Isao
    Katakami, Nobuyuki
    Takeda, Koji
    Takayama, Koichi
    Sawa, Toshiyuki
    Saito, Hiroshi
    Harada, Masao
    Yokota, Soichiro
    Ando, Kiyoshi
    Saito, Yuko
    Ohashi, Yasuo
    Eguchi, Kenji
    ONCOLOGY LETTERS, 2019, 17 (01) : 1320 - 1326
  • [29] Clinicopathological Factors in Non-Small Cell Lung Cancer Patients with Bone Metastases
    Ulas, Arife
    Bilici, Ahmet
    Durnali, Ayse
    Tokluoglu, Saadet
    Akinci, Sema
    Silay, Kamile
    Oksuzoglu, Berna
    Alkis, Necati
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S535 - S535
  • [30] Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review
    Hendriks, Lizza E. L.
    Hermans, Bregtje C. M.
    van den Beuken-van Everdingen, Marieke H. J.
    Hochstenbag, Monique M. H.
    Dingemans, Anne-Marie C.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : 155 - 173